Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Cancer Research and Clinical Oncology
Published in: Journal of Cancer Research and Clinical Oncology 8/2010

01-08-2010 | Original Paper

Clinical significance of pAKT and CD44v6 overexpression with breast cancer

Authors: Pei Yu, Ling Zhou, Weifeng Ke, Ke Li

Published in: Journal of Cancer Research and Clinical Oncology | Issue 8/2010

Login to get access

Abstract

Purpose

CD44v6 contributes to apoptosis resistance and metastasis via upregulated activity of the PI3K/AKT pathway. The purpose of this study was to investigate the expression patterns and predictive value of phosphorylated AKT (pAKT) and CD44v6 in breast cancer tissues.

Methods

Expression of pAkt and CD44v6 protein was detected using immunohistochemistry in breast cancer tissues and lymph node tissues in 98 patients. The correlation between the expression of pAkt, CD44v6 and other disease-related characteristics was investigated. The prognostic value of pAKT and CD44v6 overexpression for overall survival (OS) and disease free survival (DFS) was determined.

Results

37 cases (37.8%) were observed as positive for pAkt expression, and 38 cases (38.8%) for CD44V6 overexpression. Staining was positive for pAKT in 20 of 38 (52.6%) CD44v6(+) and 17 of 60 (28.3%) CD44v6(−) (P = 0.016). A progressively increased trend of CD44v6 overexpression was observed from node(−) primary breast cancer tissues to node(+) primary cancer tissues to node(+) lymph tissues (P = 0.000). In univariate analysis lymph node status, pAKT and CD44V6 were significantly associated with a decreased OS and DFS. Multivariate analysis revealed that CD44v6 status was associated with a reduced OS (P = 0.003), and pAKT and CD44v6 with a shorter DFS (P = 0.012 and 0.016, respectively).

Conclusions

Our data suggested that there had an intensive relationship between pAKT and CD44v6 expression in breast cancer tissues. The overexpression of CD44v6 was an independent prognostic marker for predicting OS and DFS of breast cancer patients.
Literature
Al-Hajj M, Wicha MS, Benito-Hernandez A et al (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100(7):3983–3988CrossRefPubMed
Andre F, Nahta R, Conforti R et al (2008) Expression patterns and predictive value of phosphorylated AKT in early-stage breast cancer. Ann Oncol 19(2):315–320CrossRefPubMed
Ayroldi E, Cannarile L, Migliorati G et al (1995) CD44 (Pgp-1) inhibits CD3 and dexamethasone-induced apoptosis. Blood 86(7):2672–2678PubMed
Bates RC, Elith CA, Thorne RF et al (1998) Engagement of variant CD44 confers resistance to anti-integrin antibody-mediated apoptosis in a colon carcinoma cell line. Cell Adhes Commun 6(1):21–38CrossRefPubMed
Berner HS, Suo Z, Risberg B et al (2003) Clinicopathological associations of CD44 mRNA and protein expression in primary breast carcinomas. Histopathology 42(6):546–554CrossRefPubMed
Bourguignon LY (2008) Hyaluronan-mediated CD44 activation of RhoGTPase signaling and cytoskeleton function promotes tumor progression. Semin Cancer Biol 18(4):251–259CrossRefPubMed
Bourguignon LY, Singleton PA, Zhu H et al (2003) Hyaluronan-mediated CD44 interaction with RhoGEF and Rho kinase promotes Grb2-associated binder-1 phosphorylation and phosphatidylinositol 3-kinase signaling leading to cytokine (macrophage-colony stimulating factor) production and breast tumor progression. J Biol Chem 278(32):29420–29434CrossRefPubMed
Franke TF, Kaplan DR, Cantley LC (1997) PI3K: downstream AKTion blocks apoptosis. Cell 88(4):435–437CrossRefPubMed
Friedrichs K, Franke F, Lisboa BW et al (1995) CD44 isoforms correlate with cellular differentiation but not with prognosis in human breast cancer. Cancer Res 55(22):5424–5433PubMed
Ghatak S, Misra S, Toole BP (2002) Hyaluronan oligosaccharides inhibit anchorage-independent growth of tumor cells by suppressing the phosphoinositide 3-kinase/Akt cell survival pathway. J Biol Chem 277(41):38013–38020CrossRefPubMed
Gunthert U, Hofmann M, Rudy W et al (1991) A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 65(1):13–24CrossRefPubMed
Gunthert AR, Strater J, von Reyher U et al (1996) Early detachment of colon carcinoma cells during CD95(APO-1/Fas)-mediated apoptosis. I. De-adhesion from hyaluronate by shedding of CD44. J Cell Biol 134(4):1089–1096CrossRefPubMed
Herrera-Gayol A, Jothy S (1999) Adhesion proteins in the biology of breast cancer: contribution of CD44. Exp Mol Pathol 66(2):149–156CrossRefPubMed
Herrlich P, Zoller M, Pals ST et al (1993) CD44 splice variants: metastases meet lymphocytes. Immunol Today 14(8):395–399CrossRefPubMed
Hudson DL, Sleeman J, Watt FM (1995) CD44 is the major peanut lectin-binding glycoprotein of human epidermal keratinocytes and plays a role in intercellular adhesion. J Cell Sci 108(Pt 5):1959–1970PubMed
Jansen RH, Joosten-Achjanie SR, Arends JW et al (1998) CD44v6 is not a prognostic factor in primary breast cancer. Ann Oncol 9(1):109–111CrossRefPubMed
Janssen EA, Soiland H, Skaland I et al (2007) Comparing the prognostic value of PTEN and Akt expression with the Mitotic Activity Index in adjuvant chemotherapy-treated node-negative breast cancer patients aged <55 years. Cell Oncol 29(1):25–35PubMed
Jones PF, Jakubowicz T, Hemmings BA (1991) Molecular cloning of a second form of rac protein kinase. Cell Regul 2(12):1001–1009PubMed
Kamikura DM, Khoury H, Maroun C et al (2000) Enhanced transformation by a plasma membrane-associated met oncoprotein: activation of a phosphoinositide 3’-kinase-dependent autocrine loop involving hyaluronic acid and CD44. Mol Cell Biol 20(10):3482–3496CrossRefPubMed
Katso R, Okkenhaug K, Ahmadi K et al (2001) Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu Rev Cell Dev Biol 17:615–675CrossRefPubMed
Kaufmann M, Heider KH, Sinn HP et al (1995) CD44 variant exon epitopes in primary breast cancer and length of survival. Lancet 345(8950):615–619CrossRefPubMed
Kim Y, Lee YS, Choe J et al (2008) CD44-epidermal growth factor receptor interaction mediates hyaluronic acid-promoted cell motility by activating protein kinase C signaling involving Akt, Rac1, Phox, reactive oxygen species, focal adhesion kinase, and MMP-2. J Biol Chem 283(33):22513–22528CrossRefPubMed
Klingbeil P, Marhaba R, Jung T et al (2009) CD44 variant isoforms promote metastasis formation by a tumor cell-matrix cross-talk that supports adhesion and apoptosis resistance. Mol Cancer Res 7(2):168–179CrossRefPubMed
Knuefermann C, Lu Y, Liu B et al (2003) HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene 22(21):3205–3212CrossRefPubMed
Lee JL, Wang MJ, Sudhir PR et al (2007) Osteopontin promotes integrin activation through outside-in and inside-out mechanisms: OPN-CD44V interaction enhances survival in gastrointestinal cancer cells. Cancer Res 67(5):2089–2097CrossRefPubMed
Lester BR, McCarthy JB (1992) Tumor cell adhesion to the extracellular matrix and signal transduction mechanisms implicated in tumor cell motility, invasion and metastasis. Cancer Metastasis Rev 11(1):31–44CrossRefPubMed
Ma W, Deng Y, Zhou L (2005) The prognostic value of adhesion molecule CD44v6 in women with primary breast carcinoma: a clinicopathologic study. Clin Oncol (R Coll Radiol) 17(4):258–263
Marhaba R, Freyschmidt-Paul P, Zoller M (2006) In vivo CD44-CD49d complex formation in autoimmune disease has consequences on T cell activation and apoptosis resistance. Eur J Immunol 36(11):3017–3032CrossRefPubMed
Modi S, DiGiovanna MP, Lu Z et al (2005) Phosphorylated/activated HER2 as a marker of clinical resistance to single agent taxane chemotherapy for metastatic breast cancer. Cancer Invest 23(6):483–487CrossRefPubMed
Sarbassov DD, Guertin DA, Ali SM et al (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307(5712):1098–1101CrossRefPubMed
Schmitz KJ, Otterbach F, Callies R et al (2004) Prognostic relevance of activated Akt kinase in node-negative breast cancer: a clinicopathological study of 99 cases. Mod Pathol 17(1):15–21CrossRefPubMed
Stal O, Perez-Tenorio G, Akerberg L et al (2003) Akt kinases in breast cancer and the results of adjuvant therapy. Breast Cancer Res 5(2):R37–R44CrossRefPubMed
Subramaniam V, Vincent IR, Gardner H et al (2007) CD44 regulates cell migration in human colon cancer cells via Lyn kinase and AKT phosphorylation. Exp Mol Pathol 83(2):207–215CrossRefPubMed
Sun M, Wang G, Paciga JE et al (2001) AKT1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. Am J Pathol 159(2):431–437PubMed
Tokunaga E, Kataoka A, Kimura Y et al (2006a) The association between Akt activation and resistance to hormone therapy in metastatic breast cancer. Eur J Cancer 42(5):629–635CrossRefPubMed
Tokunaga E, Kimura Y, Oki E et al (2006b) Akt is frequently activated in HER2/neu-positive breast cancers and associated with poor prognosis among hormone-treated patients. Int J Cancer 118(2):284–289CrossRefPubMed
Tulasne D, Foveau B (2008) The shadow of death on the MET tyrosine kinase receptor. Cell Death Differ 15(3):427–434CrossRefPubMed
Wu Y, Mohamed H, Chillar R et al (2008) Clinical significance of Akt and HER2/neu overexpression in African-American and Latina women with breast cancer. Breast Cancer Res 10(1):R3CrossRefPubMed
Zhou X, Tan M, Stone Hawthorne V et al (2004) Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers. Clin Cancer Res 10(20):6779–6788CrossRefPubMed
Metadata
Title
Clinical significance of pAKT and CD44v6 overexpression with breast cancer
Authors
Pei Yu
Ling Zhou
Weifeng Ke
Ke Li
Publication date
01-08-2010
Publisher
Springer-Verlag
Published in
Journal of Cancer Research and Clinical Oncology / Issue 8/2010
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-010-0779-x

Other articles of this Issue 8/2010

Journal of Cancer Research and Clinical Oncology 8/2010 Go to the issue

Original Paper

(−)-Epigallocatechin-3-gallate induces apoptosis and suppresses proliferation by inhibiting the human Indian Hedgehog pathway in human chondrosarcoma cells

Review

Bisphosphonate-induced osteonecrosis of the jaw: a review of 2,400 patient cases

Letter to the Editor

BRAF mutation predicts resistance to anti-EGFR monoclonal antibodies in wild-type KRAS metastatic colorectal cancer

Original Paper

Semi-quantitative detection of GADD45-gamma methylation levels in gastric, colorectal and pancreatic cancers using methylation-sensitive high-resolution melting analysis

Original Paper

Efficacy of a methyl ester of 5-aminolevulinic acid in photodynamic therapy for ovarian cancers

Original Paper

Identification of HTA as a novel-specific marker for human hepatocellular carcinoma
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits